Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40

Benzinga Newsdesk www.benzinga.com Positive 50.6%

Neg 0% Neu 0% Pos 50.6%

Oppenheimer analyst Jeff Jones initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $40.